Daratumumab was developed by Janssen Biotech and Genmab Inc. And first approved in 2015. It was initially approved for relapsed/refractory multiple myeloma, has considerably improved multiple myeloma outcomes either as monotherapy or in combination with other course of therapy and thus, is now being used as frontline therapy in patients with newly diagnosed multiple myeloma.